Loading
A phase 2 trial of Atezolizumab and Tiragolumab in bladder & urothelial cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer is a phase 2 interventional study registered as NCT05645692 by Hoffmann-La Roche, with 204 participants enrolled, started 2023-04-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: Atezolizumab, Tobemstomig and Tiragolumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TIGIT blockade, Tiragolumab, Flatiron Health (Roche), T-cell exhaustion and CAR-T persistence and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, T-cell exhaustion and CAR-T persistence, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/